Weinbergweg 22
Halle 06120
Germany
49 345 555 9900
https://www.vivoryon.com
Secteur(s):
Secteur d’activité:
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Frank T. Weber M.D. | Chairman of the Management Board, CEO, Chief Medical Officer & Executive Director | 250,32k | S.O. | 1960 |
Ms. Anne Doering C.F.A. | CSO & Investor Relations Officer, CFO, Member of the Management Board and Executive Director | 219,12k | S.O. | 1973 |
Dr. Michael Schaeffer Ph.D. | Chief Business Officer, Member of the Management Board & Executive Director | 325k | S.O. | 1969 |
Dr. Manuela Bader | Director of Investor Relations & Communications | S.O. | S.O. | S.O. |
Dr. Konrad Glund | Co-Founder & Advisor | 222,11k | S.O. | 1953 |
Dr. Hendrik Liebers | Advisor | 319,2k | S.O. | 1971 |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
L’ISS Governance QualityScore de Vivoryon Therapeutics N.V. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..